BWAY - Brainsway Ltd.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
10.49
0.00 (0.00%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close10.49
Open10.24
Bid10.16 x 1000
Ask10.30 x 1000
Day's Range10.20 - 10.49
52 Week Range8.00 - 12.39
Volume9,187
Avg. Volume42,330
Market Cap115.265M
Beta (3Y Monthly)0.60
PE Ratio (TTM)N/A
EPS (TTM)-0.88
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est16.69
Trade prices are not sourced from all markets
  • GlobeNewswire3 days ago

    BrainsWay Announces Shipment of 100th Deep Transcranial Magnetic Stimulation Helmet for the Treatment of Obsessive-Compulsive Disorder

    Since receiving De Novo clearance from FDA in August 2018, the Company has shipped OCD coils to 100 sites across the U.S. JERUSALEM and HACKENSACK, N.J., June 24, 2019 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE:BWAY) (BrainsWay” or the “Company”), a commercial stage medical device company focused on the development and sale of non-invasive neuromodulation products using the Company’s proprietary Deep Transcranial Magnetic Stimulation system (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD), today announced the shipment of the 100th Deep TMS helmet for the treatment of OCD in adults since receiving De Novo clearance from the U.S. Food and Drug Administration for this indication in August 2018.

  • GlobeNewswire10 days ago

    Brainsway Announces Changes to its Board of Directors

    Professor Abraham Zangen, Ph.D., a pioneering scientist in the field of TMS, has been appointed as a director. In addition, Ms. Eti Mitrany’s tenure as a director has been extended.  Professor Zangen’s and Ms. Mitrany’s tenure will expire at the Company’s next general meeting of shareholders.  Finally, Ms. Eynat Tsafrir has completed her tenure on Brainsway’s Board of Directors.

  • GlobeNewswire14 days ago

    BrainsWay to Present at the 2019 Raymond James Life Sciences and MedTech Conference

    JERUSALEM and HACKENSACK, N.J., June 13, 2019 -- BrainsWay Ltd. (NASDAQ & TASE:BWAY) (BrainsWay” or the “Company”), a commercial stage medical device company focused on the.

  • GlobeNewswire22 days ago

    “After the Smoke Clears” Brings Hope to Community on the Heels of Mental Health Awareness Month

    Calabasas Behavioral Health, a leading mental health service provider in Southern California, announced today that they are lending their time and expertise, in partnership with BrainsWay, the global leader in the advanced noninvasive treatment of brain disorders, to host “After the Smoke Clears.” The first of its kind event, free and open to the public, is designed to provide the local community with self-help tools, resources and support as they continue to recover from the Borderline Bar and Grill shooting and the Woolsey and Hill fires.

  • GlobeNewswire29 days ago

    Brainsway Reports First Quarter 2019 Financial Results and Operational Highlights

    JERUSALEM and HACKENSACK, N.J., May 29, 2019 -- Brainsway Ltd. (NASDAQ & TASE: BWAY) (“Brainsway” or the “Company”), a commercial stage medical device company focused on.

  • ACCESSWIRE29 days ago

    Brainsway Ltd. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 29, 2019 / Brainsway Ltd. (NASDAQ: BWAY ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 29, 2019 at 8:00 AM Eastern Time. ...

  • GlobeNewswirelast month

    Brainsway Ltd. to Host First Quarter 2019 Financial Results Conference Call on May 29, 2019

    Brainsway Ltd. (NASDAQ & TASE: BWAY) (“Brainsway”), a commercial stage medical device company focused on the development and sale of non-invasive neuromodulation products using the Company’s proprietary Deep Transcranial Magnetic Stimulation system (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD), today announced that it will report its first quarter 2019 financial results and operational highlights on Wednesday, May 29, 2019. The Company will host a conference call on Wednesday, May 29, 2019 at 8:00 a.m. EDT to review the financial results and operational highlights. The conference call will be broadcast live and will be available for replay for 30 days on the Company's website, https://investors.brainsway.com/financial-calendar.

  • GlobeNewswirelast month

    BrainsWay Announces its Multicenter Smoking Cessation Study Has Reached Target Enrollment

    BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay”) today announced it reached target recruitment for its multicenter study assessing the safety and efficacy of its deep transcranial magnetic stimulation system (Deep TMS) intended for use as an aid in smoking cessation in patients suffering from chronic smoking addiction. Yaacov Michlin, President and Chief Executive Officer of BrainsWay, said, “We believe there is a considerable unmet need for a safe and efficient solution for cigarette addiction. BrainsWay’s Deep TMS device is designed to effectively stimulate deep and broad areas of the brain.

  • Carolina Partners in Mental HealthCare Expands Treatment Offerings to Include Revolutionary Mental Health Technology for Obsessive-Compulsive Disorder in North Carolina
    PR Newswirelast month

    Carolina Partners in Mental HealthCare Expands Treatment Offerings to Include Revolutionary Mental Health Technology for Obsessive-Compulsive Disorder in North Carolina

    RALEIGH, N.C., May 13, 2019 /PRNewswire/ -- Carolina Partners, one of the most prominent mental and behavioral practices in the country, announced plans to offer patients access to BrainsWay's Deep Transcranial Magnetic Stimulation (Deep TMS) therapy for Obsessive-Compulsive Disorder (OCD). It will be one of the first practices in the area to provide Deep TMS for OCD, following its success in using Deep TMS to treat patients with depression.

  • GlobeNewswire2 months ago

    Achieve TMS East Celebrates the Opening of its Dorchester Location

    Achieve TMS East, Massachusetts’ largest provider of Deep Transcranial Magnetic Stimulation (Deep TMS) therapy for the treatment of Depression and Obsessive-Compulsive Disorder (OCD), is pleased to announce the opening of its newest center in Dorchester, MA. Achieve TMS East will be celebrating the opening of its Dorchester office with a Ribbon Cutting Ceremony and Open House on Friday, May 17, from 12:00 – 1:30 pm at the Carney Medical building located at 2110 Dorchester Avenue, Suite 308, Dorchester, MA 02124. Among the guests will be Marjorie Pierce, Director of Operations for Achieve TMS East.

  • GlobeNewswire2 months ago

    Brainsway Ltd. Announces Closing of Initial Public Offering

    Brainsway Ltd. (NASDAQ: BWAY and TASE: BRIN) (“Brainsway”) today announced that it has closed its initial public offering of 2,500,000 American Depositary Shares (“ADSs”), each representing two ordinary shares of Brainsway, at a public offering price of $11.00 per ADS. The gross proceeds to Brainsway from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses, are approximately $27.5 million. The underwriters have been granted an option to purchase up to an additional 375,000 ADSs offered by Brainsway for a period of 30 days after the pricing date.

  • GlobeNewswire2 months ago

    Brainsway Ltd. Announces Pricing of Initial Public Offering of 2.5 Million American Depositary Shares

    Brainsway Ltd. (NASDAQ: BWAY and TASE: BRIN) (“Brainsway”) today announced that it has priced its initial public offering of 2,500,000 American Depositary Shares (“ADSs”), each representing two ordinary shares of Brainsway, at a public offering price of $11.00 per ADS. The gross proceeds to Brainsway from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $27.5 million.

  • Benzinga2 months ago

    Brainsway IPO: What You Need To Know

    About 16.2 million Americans have an episode of major depressive disorder each year, according to the National Institute of Mental Health. About 2.24 million have obsessive-compulsive disorder. Brainsway ...

  • Benzinga2 months ago

    IPO Outlook For The Week: Pinterest, Zoom, Biotechs, Minerals And Catastrophe Insurance

    For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . The IPO dates below are expected but not confirmed. Brainsway Ltd (BWAY) will issue 2.5 million shares at $11.94 Wednesday ...